Statistically significant lower risk is seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 29 studies from 23 independent teams in 12 countries show statistically significant improvements.
Meta analysis using the most serious outcome reported shows 30% [21‑38%] lower risk. Results are similar for higher quality and peer-reviewed studies and better for Randomized Controlled Trials.
Results are robust — in exclusion sensitivity analysis 23 of 49 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
This analysis combines the results of several different antiandrogens. Results for individual treatments may vary.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix. Other meta analyses show significant improvements with antiandrogens for mortality Cheema, Kotani, hospitalization Cheema, recovery Cheema, and progression Kotani.
2 meta analyses show significant improvements with antiandrogens for mortality
Cheema,
Kotani,
hospitalization
Cheema,
recovery
Cheema, and
progression
Kotani.
Covid Analysis et al., Mar 2024, preprint, 1 author.